Table 4.
Subgroup analysis of the association between SOX2-OT overexpression and OS in patients with different cancers.
| Sub variates | No. of trials | HR (95% CI) (FEM) | P value (FEM) | HR (95% CI) (REM) | P value (REM) | Heterogeneity I2, P | Heterogeneity Q | Heterogeneity tau2 | P between subgroup (REM) |
|---|---|---|---|---|---|---|---|---|---|
| Sample size | |||||||||
| ≥100 | 4 | 1.942[1.486; 2.539] | <0.0001 | 1.942[1.486; 2.539] | <0.0001 | 0.00%, 0.5595 | 2.0625 | <0.0001 | 0.6764 |
| ≤100 | 7 | 2.099[1.642; 2.682] | <0.0001 | 2.099[1.642; 2.682] | <0.0001 | 0.00%, 0.9777 | 1.1828 | <0.0001 | |
| Tumor type | |||||||||
| Osteosarcoma | 1 | 1.659[1.042; 2.641] | 0.0328 | 1.659[1.042; 2.641] | 0.0328 | NA, 1.0000 | <0.0001 | NA | 0.9369 |
| Pancreatic ductal adenocarcinoma | 2 | 1.887[1.203; 2.959] | 0.0057 | 1.887[1.203; 2.959] | 0.0057 | 0.00%, 0.9452 | 0.0047 | <0.0001 | |
| Cholangiocarcinoma | 2 | 2.150[1.270; 3.637] | 0.0043 | 2.150[1.270; 3.637] | 0.0043 | 0.00%, 0.9803 | 0.0006 | <0.0001 | |
| Lung cancer | 2 | 2.019[1.265; 3.222] | 0.0032 | 2.019[1.265; 3.222] | 0.0032 | 0.00%, 0.4068 | 0.6882 | <0.0001 | |
| HCC | 2 | 2.125[1.451; 3.113] | 0.0001 | 2.125[1.451; 3.113] | 0.0001 | 0.00%, 0.4559 | 0.5558 | <0.0001 | |
| Gastric cancer | 2 | 2.299[1.525; 3.467] | 0.0001 | 2.299[1.525; 3.467] | 0.0001 | 0.00%, 0.3456 | 0.8894 | <0.0001 | |
| Sample type | |||||||||
| Tissue | 9 | 2.080[1.699; 2.546] | <0.0001 | 2.080[1.699; 2.546] | <0.0001 | 0.00%, 0.9289 | 3.0847 | <0.0001 | 0.8458 |
| Mix | 1 | 1.793[1.040; 3.092] | 0.0357 | 1.793[1.040; 3.092] | 0.0357 | NA, 1.0000 | <0.0001 | NA | |
| Serum | 1 | 1.860[1.015; 3.408] | 0.0445 | 1.860[1.015; 3.408] | 0.0445 | NA, 1.0000 | <0.0001 | NA | |
| Cut-off value | |||||||||
| Median | 6 | 2.040[1.616; 2.575] | <0.0001 | 2.040[1.616; 2.575] | <0.0001 | 0.00%, 0.7362 | 2.7648 | <0.0001 | 0.9231 |
| others | 2 | 2.196[1.279; 3.771] | 0.0043 | 2.196[1.279; 3.771] | 0.0043 | 0.00%, 0.5099 | 0.4343 | <0.0001 | |
| mean | 3 | 1.935[1.379; 2.714] | 0.0001 | 1.935[1.379; 2.714] | 0.0001 | 0.00%, 0.9702 | 0.0604 | <0.0001 | |
| Analysis model | |||||||||
| Multivariate | 8 | 2.052[1.661; 2.536] | <0.0001 | 2.052[1.661; 2.536] | <0.0001 | 0.00%, 0.8533 | 3.3257 | <0.0001 | 0.8178 |
| Survival curve | 3 | 1.956[1.380; 2.773] | 0.0002 | 1.956[1.380; 2.773] | 0.0002 | 0.00%, 0.9798 | 0.0408 | <0.0001 | |
HR, hazard ratio; CI, confidence interval; OS, overall survival; HCC, hepatocellular carcinoma; FEM, fixed-effect model; REM, random-effect model; NA, not available.
I2, index for assessing heterogeneity; value ≥25% indicates a moderate to high heterogeneity.
Bold italics indicate statistically significant values (P < 0.05).